Company intelligence / Profile preview
Clearside Biomedical
Alpharetta, Georgia, United Statesclearsidebio.com ↗
- Ownership
- Public · CLSD
- Employees
- ~32
- Development stage
- Phase 3
01
Overview
Clearside has FDA approval for XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use. Their lead program CLS-AX (axitinib injectable suspension) for wet AMD is advancing to Phase 3 clinical trials.
- Therapeutic areas
- OphthalmologyOncologyEndocrinology
- Modalities
- Small moleculesinjectable suspensions
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Bausch + Lomb Ireland LimitedArctic Vision (Hong Kong) LimitedREGENXBIO, Inc.BioCryst Pharmaceuticals, Inc.Aura Biosciences, Inc.
Beyond the preview
Go deeper on Clearside Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clearside Biomedical.